Neuroprotection is a therapeutic strategy that attempts to save neurons from irreversible injury by modifying the effects of the ischemic cascade or facilitating reperfusion. Although numerous agents have shown neuroprotective effect in preclinical trials, their translation to clinical trials failed to show any meaningful effect. The Stroke Therapy Academic Industry Roundtable (STAIR) guidelines were made for performing research on neuroprotective agents in pre-clinical and clinical trials. Although the STAIR guidelines have been available for more than ten years, we still do not have any adequate neuroprotective agents. Reasons for unsuccessful translation from preclinical to clinical research can be considered along stages of drug development: 1) preclinical, 2) transitional and 3) clinical. By extending the therapeutic window for application of intravenous thrombolysis in acute stroke patients to 4.5 hours, as well as increasing the use intra-arterial thrombolysis and development of mechanical devices for thrombectomy in 6 hour period we may be able to achieve some degree of neuroprotection in acute stroke. Future therapy is likely to add to the current thrombolytic therapy with potential neuroprotective drugs or procedures. 
Introduction
Stroke is the third cause of mortality and leading cause of disability worldwide [1] and recently has been accepted as a medical emergency [2, 3] . Generally stroke can be classified to hemorrhagic (40% of total cases) and ischemic (60% of total cases) [4] . The TOAST classification classifies ischemic stroke as a result of large-vessel atherosclerotic disease, small-vessel atherosclerotic disease, a cardioembolic source, other determined etiologies, and undetermined or multiple possible etiologies [5] . Neuroprotection is a therapeutic strategy that attempts to save neurons from irreversible injury [6] [7] [8] .
Thrombolysis with tissue plasminogen activator is the only approved drug for the treatment of acute phase of ischemic stroke [9] [10] [11] . Before the thrombolysis era, clinical trials in stroke prevention were more successfull than trials in acute stroke treatment, in which neuroprotecion trials are included [12, 13] .
In last two decades, neuroprotection drug research has dramatically increased [14] [15] [16] .
Preclinical research on many pharmacological agents with different mechanisms of action showed success in neuroprotection on animal stroke models [17] . Yet in translation from preclinical to clinical randomized trials, these agents failed to demonstrate a neuroprotective effect [6, 18] . In response to numerous clinical trials on drugs in neuroprotection that have failed to demonstrate adequate effect, the Stroke Therapy Academic Industry Roundtable (STAIR) guidelines were developed in order to provide a structured process and standards for carrying out research on neuroprotective agents in pre-clinical and clinical trials [19] [20] [21] .
However, despite enormous efforts and the fact that the STAIR guidelines have been available for more than ten years, no effective neuroprotective treatment is available in ischaemic stroke [15] . 
Ischemic cascade and reperfusion injury
Ischemic cascade and reperfusion are the main mechanisms that are of interest in treatment of ischemic stroke. Brain ischemia initiates an "ischemic cascade", a complex sequence of metabolic events beginning with energy depletion that involves the generation of nitrogen oxide and free radicals through the excitation of NMDA (N-methyl-D-aspartate) receptors and intracellular influx of calcium, finally resulting in the induction of apoptotic and necrotic pathways. All these metabolic events occur within a few minutes or hours after the ischemic process and therefore may be potential sites of possible action of a neuroprotective agent [12, 22, 23] . Figure 1 shows a schematic of the ischemic cascade.
For many years it was thought that the reperfusion could prevent ischemic damage of brain in stroke, but often reperfusion damage causes additional brain tissue damage in ischemic stroke [24] . Reperfusion encourages leukocytes migration with activation of inflammatory response, release of cytokines, increased expression of leukocyte adhesion molecules on endothelium surface, occlusion of small vessels, and worsening of the ischemia [25, 26] . Also, the formation of free radicals causes mitochondrial damage that activates proapoptotic proteins that begin the programmed cell death of apoptosis. In addition to these effects, free radicals damage the DNA causing further injury to the cell membrane causing cell necrosis [27] . During the inflammatory response, phagocytes eliminate the "healthy" cells and contribute to the further free radical formation [25] . Figure 2 summarizes mechanisms of the reperfusion injury.
preclinical animal models in neuroprotection
Preclinical research can be carried out using in vitro and in vivo models. In vitro studies use neuronal or mixed cell cultures and organotypic slice preparations as model systems that recreate some of the consequences of a focal ischemic insult [28] . The three main classes of animal stroke models are global ischemia, focal ischemia, and hypoxia/ischemia (the latter exclusively in young animal). These animal stroke models can be investigated in permanent or transient cerebral arteries occlusion. The most frequently used animals in these investigations are rodents (lissencephalic species) because their cranial circulation is similar to that of humans [27] [28] [29] . The next step in drug development is testing the potential neuroprotective drug on gyrencephalic species such as dogs, pigs, and non-human primates before testing on humans [21, 28] . Modified from reference [55] . Abbreviations: CBF -cerebral blood flow, O 2 -oxygen, K e -extracellular potassium, Na i -intracellular sodium, H 2 O i -intracellular water, Ca 2+ -calcium, NO . -nitric oxide. Modified from references [11] and [47] .
models for global cerebral ischemia in rats are four-vessel occlusion (4-VO) or two-vessel occlusion (2-VO) with hypotension, and in gerbil and mouse models, two-vessel occlusion (2-VO) [28, 29] . Regional blood flow can be measured using a laser Doppler flowmetry [28, 29] . The neurological assessment of an animal model is usually evaluated by the five point scale neurological deficit score or by the new 14 point neurological scoring system [28, 32, 33] .
Further useful measurements are bloodbrain barrier function, leukocyte and platelet adhesion, cell activation and adhesion molecules expression, and protein and mRNA levels [28, 29] .
clinical trials in neuroprotection in ischemic stroke patients
Therapeutic strategies for neuroprotection aim to modify effects which occur in ischemic cascade and possibly achieve reperfusion [34] .
The neuroprotecion effect is mostly targeting neurons in penumbra [22, 35] . Their role is not simply to protect individual neurons, but also, more importantly, to protect the neurovascular unit comprised of the neuron and the supporting glial and vascular cells within its immediate environment (such as astrocytes, pericytes, microglia, oligodendrocytes, and endothelial
cells of microvessels). Studies on animal models
showed that neurons in penumbra have the ability to recover for up to four hours from the onset of ischemia [6] . Neuroprotective drugs and procedures which have been investigated can be divided according to mechanism of action into:
1) limitation of ischemic cascade, 2) glutamatemediated excitotoxicity, 3) vascular-targeted therapeutics, 4) anti-inflammatory therapy, 5)
other (e.g., hypothermia, hemicraniectomy, hemodilution, etc) [9, 36] . 
sTaIr guidelines
In response to unsuccessful developments of effective neuroprotective agents despite The most influential factor affecting the transitional stage is the genetic variability in humans. In animal models, genetic variability is highly constrained, and therefore possible drug responses are limited according to these constraints. Because of this, we cannot predict side effects that may be produced in humans by drug doses used in experimental models [14, 47] .
Another factor that may be operational is that the common use of anesthetics in preclinical trials affect outcomes, as they are administered in too small of therapeutic window to be feasibly applied to most patients [47] .
A main factor during the clinical stage that have an impact on the failure of neuroprotective agent are inadequate study design such as too small of a sample size of patients or a combination of different stroke models in the same study despite therapy being effective only against one type of the stroke. Other factors include the lack of standardation of outcome measures, and failure to achieve adequate effect and concentration of investigation drugs in plasma [15, 47] . Analyses often did not include confounders, such as co-morbidities, age and gender [34] . A newlyemerging challenge is to consider testing potential neuroprotective therapies in patients who have received intravenous thrombolysis (IV -tPA) to study the dynamic relationship of the two therapies [43] .
further perspective of clinical trials in neuroprotective agent development
The extension of a therapeutic window for application of intravenous thrombolysis in acute stroke patients for 4.5 hours, as well as
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Writing Committee, Guidelines for management of ischaemic stroke increasing the use intra-arterial thrombolysis and development of mechanical devices for thrombectomy in six hour period gives a chance for neuroprotection in acute stroke [40] . But emphasis must be given to the crucial point that both the recanalization and neuroprotective treatment be administered in acute stroke [48] [49] [50] .
Despite previous failures, clinical trials in neuroprotective agents are continuing.
The most promising neuroprotective drugs and procedures are citicoline, hypothermia, magnesium, albumins and statins [15, 51] . It is likely that the current thrombolytic therapy will be accompanied by some of the possible neuroprotective drugs or procedures [6, 8, 42, 43, 50] . There is also a possibility that in future we would use neuroprotective agents with multimodal characteristics which are acting on multiple points of the ischemic process [14] . References
